Telomir Pharmaceuticals (NASDAQ:TELO) Trading Up 2.3% – Here’s Why

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) shares rose 2.3% during mid-day trading on Wednesday . The company traded as high as $1.33 and last traded at $1.32. Approximately 179,746 shares were traded during trading, a decline of 72% from the average daily volume of 645,422 shares. The stock had previously closed at $1.29.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Telomir Pharmaceuticals Trading Up 2.3%

The stock has a market cap of $45.38 million, a price-to-earnings ratio of -3.57 and a beta of -0.46. The firm’s 50 day moving average is $1.45 and its two-hundred day moving average is $1.59.

Telomir Pharmaceuticals (NASDAQ:TELO) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. As a group, equities analysts expect that Telomir Pharmaceuticals, Inc. will post -0.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Telomir Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Bank of America Corp DE increased its stake in Telomir Pharmaceuticals by 283.9% in the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after purchasing an additional 10,880 shares during the last quarter. Nuveen LLC purchased a new stake in Telomir Pharmaceuticals in the 1st quarter valued at about $81,000. HighTower Advisors LLC acquired a new position in shares of Telomir Pharmaceuticals during the 1st quarter valued at about $139,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Telomir Pharmaceuticals during the 2nd quarter worth about $81,000. Finally, Marshall Wace LLP acquired a new stake in shares of Telomir Pharmaceuticals in the second quarter worth approximately $95,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.